InjuRecov®
DOWNLOAD PDF
DOWNLOAD PATIENT HANDOUT
FUNCTIONS / OBJECTIVE
The ingredients used in Vinco’s InjuRecov® TRIFECTA have been clinically proven to stimulate the inhibition of the COX II inflammatory pathway as well as providing the nutrients needed to help rebuild tissue. This three phase (trifecta) approach (1) suppports minor discomfort; (2) modulates inflammatory pathways; and (3) helps promote healing.
Ginger (Zingiber officinale)
Ginger, a flowering plant, whose rhizone ginger root, or simply ginger, is widely used as a spice and in alternative medicine. The active components of the ginger root are volatile oils and pungent phenol compounds, such as gingerols and shogaols.
Vinco's InjuRecov® contains 100 mg of Ginger Root Extract (Standardized to 5% gingerols) per serving
Gingerol, shogaol, and other structurally-related substances in ginger inhibit prostaglandin and leukotriene biosynthesis through suppression of 5-lipoxygenase or prostaglandin synthetase. Additionally, they can also inhibit synthesis of pro-inflammatory cytokines such as IL-1, TNF-α, and IL-8. [1,2]
Lantz et al. showed that gingerols can inhibit LPS-induced COX-2 expression while shogaol containing extracts had no effect on COX-2 expression. This data demonstrates that important compounds in ginger are capable of inhibiting PGE (2) production. [3]
Turmeric (Curcuma longa)
Turmeric is a rhizomatous herbaceous perennial plant of the ginger family, Zingiberaceae. Due largely to its anti-inflammatory properties, it has been recognized for its healthful effects.
Vinco's InjuRecov® contains 300 mg of Turmeric Rhizome Extract (Standardized to 95% curcuminoids) per serving
The anti-inflammatory effect of curcumin is most likely mediated through its ability to inhibit cyclooxygenase-2 (COX-2), lipoxygenase (LOX), and inducible nitric oxide synthase (iNOS). COX-2, LOX, and iNOS are important enzymes that mediate inflammatory processes. Improper upregulation of COX-2 and/or iNOS has been associated with the pathophysiology of certain types of inflammatory disorders. [4]
Boswellia serrata
Gum-resin extracts of Boswellia serrata have been traditionally used in alternative medicine for centuries to treat various chronic inflammatory diseases. The resinous part of Boswellia serrata possesses monoterpenes, diterpenes, triterpenes, tetracyclic triterpenic acids and four major pentacyclic triterpenic acids i.e. β-boswellic acid, acetyl-β-boswellic acid, 11-keto-β-boswellic acid and acetyl-11-keto-β-boswellic acid, responsible for inhibition of pro-inflammatory enzymes. Out of these four boswellic acids, acetyl-11-keto-β-boswellic acid is the most potent inhibitor of 5-lipoxygenase, an enzyme responsible for inflammation. [5]
Vinco's InjuRecov® contains 200 mg of Boswellia serrata Gum Extract (Standardized to 40% Boswellic Acid) per serving
DL-Phenylalanine
Phenylalanine is an essential amino acid (a building block for proteins in the body), meaning the body needs it, but cannot make it. Phenylalanine is found in 3 forms.
• L-phenylalanine, the natural form found in proteins
• D-phenylalanine (a mirror image of L-phenylalanine that is made in a laboratory)
• DL-phenylalanine, a combination of the 2 forms
D-phenylalanine (DPA) decreases pain by blocking the enzymes that break down the body’s natural painkillers. Clinical studies suggest DPA may inhibit some types of chronic pain. Certain amino acids have been found to raise pain thresholds and increase tolerance to pain. One of these, a synthetic amino acid called D-phenylalanine (DPA), decreases pain by blocking the enzymes that break down endorphins and enkephalins, the body’s natural pain-killing chemicals. [6,7]
Vinco's InjuRecov® contains 500 mg of DL-Phenylalanine per serving
Methylsulfonylmethane (MSM)
MSM is an organic sulfur compound. Sulfur is needed to form connective tissue. MSM also seems to act as an analgesic by lessening nerve impulses that transmit pain.
Methylsulfonylmethane, derived from Dimethyl sulfoxide or DMSO, have been used to treat arthritic conditions [8]. DMSO is converted in the body to MSM and as MSM remains in the body for longer than DMSO [9], it is suggested that many of the beneficial effects of DMSO are due to the long lasting fraction of DMSO which is converted to MSM [10].
Both have similar pharmacological properties and their putative effects and mechanisms have been reviewed previously (MSM [11-13]; DMSO [14–17]; both [18, 19]). MSM and DMSO have been reported to reduce peripheral pain [20–22], inflammation [23] and arthritis [24], and might inhibit the degenerative changes occurring in OA [25]. These compounds may act through their ability to stabilize cell membranes, slow or stop leakage from injured cells and scavenge hydroxyl free radicals which trigger inflammation [21, 23, 26-31]. Their sulfur content may also rectify dietary deficiencies of sulfur improving cartilage formation [32, 33].
Vinco's InjuRecov® contains 500 mg of Methylsulfonylmethane (MSM) per serving
Collagen (Type II)
Type II Collagen is the primary form of collagen contained in cartilage. Type II Collagen Extracts contain the amino acids found in the framework of human cartilage and can support the production of collagen in the body. These extracts reportedly aid in reducing the destruction of collagen within the body by “giving themselves up” in times of trauma. They also may provide anti-inflammatory activity and may improve joint flexibility.
Vinco's InjuRecov® contains 100 mg of Collagen (Type II) per serving
Deglycyrrhizinated (DGL) Licorice Root
Although licorice is most recognized as a flavoring agent, it has a long history as a medicinal herb. It has been used to relieve symptoms in individuals with adrenal insufficiency and as a treatment for upper respiratory symptoms. DGL Licorice may be beneficial in a variety of gastrointestinal disorders, particularly in peptic ulcer disease and inflammatory disorders. Licorice also is reported to inhibit prostaglandin and leukotriene synthesis.
Vinco's InjuRecov® contains 200 mg of DGL Licorice per serving
* These statements have not been evaluated by the FDA. This product is not intended to treat, cure, or prevent any disease.
REFERENCES
1. Tjendraputra E, Tran VH, Liu-Brennan D, Roufogalis BD, Duke CC. Effect of ginger constituents and synthetic analogues on cyclooxygenase-2 enzyme in intact cells. Bioorganic Chem. 2001;29:156–63. [PubMed]
2. Verma SK, Singh M, Jain P, Bordia A. Protective effect of ginger, Zingiber officinale Rosc on experimental atherosclerosis in rabbits. Indian J Exp Biol. 2004;42:736–8. [PubMed]
3. Lantz RC, Chen GJ, Sarihan M, Sólyom AM, Jolad SD, Timmermann BN. The effect of extracts from ginger rhizome on inflammatory mediator production. Phytomedicine. 2007;14:123–8. [PubMed]
4. Antioxidant and anti-inflammatory properties of curcumin. Menon VP, Sudheer AR. Adv Exp Med Biol. 2007;595:105-25. Review. PMID: 17569207
5. Boswellia serrata, a potential antiinflammatory agent: an overview. Siddiqui MZ.Indian J Pharm Sci. 2011 May;73(3):255-61. doi: 10.4103/0250-474X.93507. PMID: 22457547
6. 10. Ehrenpreis S. Analgesic properties of enkephalinase inhibitors: animal and human studies. Prog Clin Biol Res 1985;192:363-70.
7. Guisti P, Carrara M, Cima L, Borin G. Antinociceptive effect of some carboxypeptidase A inhibitors in comparison with D-phenylalanine. Eur J Pharmacol 1985;116:287-92.
8. Deal CL, Moskowittz RW. Neutriceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chondrotin sulphate and collagen hydrolysate. Rheumatic Disease Clinics of North America. 1999;25:379–395. [PubMed]
9. Bertken R. “Crystalline DMSO”: DMSO2. Arthritis and Rheumatism. 1983;26(5):693–694. [PubMed]
10. Kolb KH, Janicke G, Kramer M, Schulze PE. Adsorption, distribution and elimination of labeled DMSO in man and animal. Annals of the New York Academy of Sciences. 1967;141:85–95. [PubMed]
11. Ameye LG, Chee WSS. Osteoarthritis and nutrition. From nutraceuticals to functional foods: a systematic review of the scientific evidence. Arthritis Research and Therapy. 2006;8(4, article R127) [PMC free article] [PubMed]
12. Methylsulfonylmethane (MSM). Monograph. Alternative Medicine Review. 2003;8:438–441. [PubMed]
13. Cronin JR, Ballen K. The biochemistry of alternative therapies: methylsulfonylmethane: nutraceutical of the next century? Alternative and Complementary Therapies. 1999;5(6):386–389.
14. Demos CH, Beckloff GL, Donin MN, Oliver PM. Dimethyl sulfoxide in musculoskeletal disorders. Annals of the New York Academy of Sciences. 1967;141(1):517–523. [PubMed]
15. Jimenez RAH, Willkens RF. Dimethyl sulfoxide: a perspective of its use in rheumatic diseases. Journal of Laboratory and Clinical Medicine. 1982;100(4):489–500. [PubMed]
16. Trice JM, Pinals RS. Dimethyl sulfoxide: a review of its use in the rheumatic disorders. Seminars in Arthritis and Rheumatism. 1985;15(1):45–60. [PubMed]
17. Rosenstein ED. Topical agents in the treatment of rheumatic disorders. Rheumatic Disease Clinics of North America. 1999;25(4):899–918. [PubMed]
18. Ely A, Lockwood B. What is the evidence for the safety and efficacy of dimethyl sulfoxide and methylsulfonylmethane in pain relief? Pharmaceutical Journal. 2002;269(7223):685–687.
19. Brien S, Prescott P, Bashir N, Lewith H, Lewith G. Systematic review of the nutritional supplements dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) in the treatment of osteoarthritis. Osteoarthritis and Cartilage. 2008;16(11):1277–1288. [PubMed]
20. Evans MS, Reid KH, Sharp JB. Dimethyl sulphoxide blocks conduction in peripheral nerve C fibres: a possible mode of action. Neuroscience Letters. 1993;150:145–148. [PubMed]
21. Muir M. DMSO: many uses, much controversy. Alternative and Complementary Therapies. 1996;2:230–235.
22. Jacob SW, Herschler R. Dimethyl sulfoxide after twenty years. Annals of the New York Academy of Sciences. 1983;411:14–18. [PubMed]
23. Beilke MA, Collins-Lech C, Sohnle PG. Effects of dimethyl sulphoxide on the oxidative function of human neutraphils. Journal of Laboratory and Clinical Medicine. 1987;110:91–96. [PubMed]
24. Paulus HE. FDA Arthritis Advisory Committee meeting: methotrexate; guidelines for the clinical evaluation of antiinflammatory drugs; DMSO in scleroderma. Arthritis and Rheumatism. 1986;29(10):1289–1290. [PubMed]
25. Muravev I, Venikova M, Pleslovskaia GN, Riazantseva TA, Sigidin IA. Effect of dimethylsulphoxide and dimethyl sulfone on a destructive process in the joints of mice with spontaneous arthritis. Patologicheskaia Fiziologiia I Eksperimentalnaia Terapiia. 1991;2:37–39. [PubMed]
26. Brayton CF. Dimethyl sulfoxide (DMSO): a review. The Cornell Veterinarian. 1986;76(1):61–90. [PubMed]
27. Ebisuzaki K. Asprin and methylsulphonylmethane (MSM): a search for common mechanisms, with implictions for cancer prevention. Anticancer Research. 2003;23:453–458. [PubMed]
28. Alam SS, Layman DL. Dimethyl sulphoxide inhibition of prostacylin production in culture aortic endothelial cells. Annals of the New York Academy of Sciences. 1983;411:318–320. [PubMed]
29. Fox RB, Fox WK. Dimethyl sulphoxide prevents hydroxyl radical mediated depolymerisation of hyaluronic acid. Annals of the New York Academy of Sciences. 1983;411:13–17. [PubMed]
30. Morton J, Moore R. Lupus nephritis and deaths are diminished in B/W mice drinking 3% water solution of dimethyl sulphoxide or dimethyl sulfone. Journal of Leukocyte Biology. 1986;40:p. 322.
31. Hasegawa T, Ueno S, Kumamoto S, Yoshikai Y. Suppressive effect of methylsulfonylmethane (MSM) on type II collagen-induced arthritis in DBA/1J mice. Japanese Pharmacology and Therapeutics. 2004;32(7):421–427.
32. Rizzo R, Grandolfo M, Godeas C, Jones KW, Vittur F. Calcium, sulfur, and zinc distribution in normal and arthritic articular equine cartilage: a synchrotron radiation-induced X-ray emission (SRIXE) study. Journal of Experimental Zoology. 1995;273(1):82–86. [PubMed]
33. Parcell S. Sulfur in human nutrition and applications in medicine. Alternative Medicine Review. 2002;7(1):22–44. [PubMed]